Intracranial hemorrhage in adult patients with hematological malignancies

Table 3 Univariate analysis of 30-day outcome of ICH among patients with hematological malignancies.

	Alive (n = 26)	Dead (n = 46)	Univariate analysis, Pvalue	Multivariate analysis, Pvalue (odds ratio; 95% CI)
Gender:			0.604
Male	16	32
Female	10	14
Age			>0.999
≥60 years	12	20
<60 years	14	26
Hematological malignancies			0.679
AML	14	29
APL	5	4
ALL	2	3
Lymphoma	3	4
Myeloma	2	6
Remission status			0.448
Yes	4	4
No	22	42
Post HSCT			0.473
Yes	2	7
No	24	39
Underlying hypertension			>0.999
Yes	7	12
No	19	34
Sepsis			0.050
Yes	8	26
No	18	20
CNS involvement			>0.999
Yes	2	4
No	24	42
Subarachnoid hemorrhage			0.007	0.021 (10.9; 1.3 to 88.9)
Yes	1	14
No	25	32
Multifocal hemorrhage			0.006	0.026 (4.7; 1.6 to 14.0)
Yes	6	27
No	20	19
Surgical intervention			0.085
Yes	7	4
No	19	41
Leukocyte count			>0.999
≥100,000 cells/μl	4	8
<100,000 cells/μl	22	38
Platelet count			0.802
≥20,000 cells/μl	16	30
<20,000 cells/μl	10	16
Prolongation of prothrombin time			0.013	0.008 (10.9; 1.3 to 85.5)
INR ≥1.5	1	14
INR <1.5	24	32

ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; ICH = intracranial hemorrhage; INR = international normalized ratio.

ISSN: 1741-7015